ArticleCancer communications (London, England)2024

Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study.

Ziyan Tong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.